ORKA

+ Watchlist + Portfolio

Oruka Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $109.69
52-Week Range: $14.10 – $115.52
Market Cap: $6.94B
P/E (TTM): —
EPS (TTM): -2.04
Dividend Yield: —

Advanced Metrics

Price/Book: 5.76
PEG Ratio: —
Return on Equity: -18.23%
Return on Assets: -12.95%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 38.51
Debt/Equity: 0.00
Total Debt: $2.55M
Free Cash Flow: $-65.03M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $6.07B

ORKA Income statement, annual periods, in USD
USD	FY2025
Revenue	$0.00
Research & Development	$100.64M
Selling, General & Admin	$21.41M
Operating Expenses	$122.05M
Operating Income	-$122.05M
EBITDA	-$105.35M
Pretax Income	-$105.43M
Net Income	-$105.43M
Diluted EPS	-1.85
Diluted Shares	45.61M

ORKA Cash Flow statement, annual periods, in USD
USD	FY2025
Operating Cash Flow	-$88.21M
Capital Expenditure	-$209.00K
Free Cash Flow	-$88.42M
Depreciation & Amortisation	$83.00K
Stock-Based Compensation	$24.24M
Investing Cash Flow	-$96.75M
Financing Cash Flow	$170.31M
Net Change in Cash	-$14.64M

ORKA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$19.93M	$24.09M	$28.99M	$27.64M	$29.14M
Selling, General & Admin	$5.16M	$4.34M	$5.12M	$6.79M	$7.29M
Operating Expenses	$25.09M	$28.43M	$34.10M	$34.43M	$36.43M
Operating Income	-$25.09M	-$28.43M	-$34.10M	-$34.43M	-$36.43M
EBITDA	-$25.07M	-$24.55M	-$30.26M	-$29.55M	-$36.39M
Pretax Income	-$21.00M	-$24.57M	-$30.28M	-$29.58M	-$31.82M
Net Income	-$21.00M	-$24.57M	-$30.28M	-$29.58M	-$31.82M
Diluted EPS	-0.40	-0.46	-0.55	—	-0.48
Diluted Shares	41.82M	42.23M	44.20M	—	55.31M

ORKA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$83.57M	$65.40M	$91.25M	$46.94M	$49.52M
Current Assets	$352.08M	$332.01M	$355.16M	$343.86M	$395.25M
Total Assets	$377.11M	$357.42M	$509.25M	$488.62M	$504.48M
Current Liabilities	$11.72M	$12.11M	$20.97M	$15.37M	$16.63M
Total Debt	$947.00K	$2.33M	$1.91M	$1.93M	$1.81M
Total Liabilities	$12.39M	$13.78M	$22.46M	$19.62M	$20.69M
Retained Earnings	-$104.72M	-$129.30M	-$159.57M	-$189.16M	-$220.98M
Shareholders' Equity	$364.73M	$343.64M	$486.79M	$469.00M	$483.79M
Working Capital	$340.36M	$319.90M	$334.20M	$328.48M	$378.62M

ORKA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$20.87M	-$23.14M	-$21.60M	-$22.59M	-$23.58M
Capital Expenditure	-$13.00K	-$34.00K	-$99.00K	-$63.00K	-$73.00K
Free Cash Flow	-$20.88M	-$23.18M	-$21.70M	-$22.66M	-$23.65M
Depreciation & Amortisation	$16.00K	$19.00K	$20.00K	$28.00K	$43.00K
Stock-Based Compensation	$4.88M	$5.08M	$10.16M	$4.12M	$6.97M
Investing Cash Flow	$42.87M	$4.86M	-$122.45M	-$22.02M	-$14.44M
Financing Cash Flow	$0.00	$109.00K	$169.91M	$298.00K	$40.60M
Net Change in Cash	$22.00M	-$18.18M	$25.86M	-$44.32M	$2.58M

Market Snapshot

About

Oruka Therapeutics is a clinical-stage biotechnology company developing innovative biologics for chronic skin diseases. The company focuses on creating long-acting antibody therapies for conditions like plaque psoriasis and atopic dermatitis that require less frequent dosing than current treatments.